Table 3.

Overall survival based on patient, tumor and treatment characteristics.

Characteristics	N (events)	Univariate analysis			Multivariate analysis*
		p-value	HR	95% CI	p-value	HR	95% CI
Pre-RT PSA (ng/ml)
<0.5	81 (15)		1.00			1.00
≥0.5	115 (39)	0.028	1.95	1.07 – 3.54	0.037	1.95	1.04–3.64
Clinical T Stage
T1–T2a	55 (10)		1.00
T2b–T2c	47 (12)	0.60	0.79	0.34 – 1.86
T3–T4	88 (32)	0.63	0.83	0.40 – 1.73
Gleason Score
5–6	15 (4)		1.00			1.00
7	57 (17)	0.25	1.92	0.64 – 5.77	0.37	1.69	0.54–5.25
8–10	124 (33)	0.39	1.59	0.56 – 4.51	0.63	1.30	0.44–3.86
iPSA (ng/ml)
≤10	60 (11)		1.00
10.1–20	41 (10)	0.96	0.98	0.41 – 2.32
>20	95 (33)	0.36	1.38	0.69 – 2.75
iPSA (ng/ml)	196 (54)	0.80	1.00	0.99 – 1.01
Duration of neoadjuvant ADT (mo)	194 (54)	0.96	1.00	0.85 – 1.18
Total duration of ADT (yrs)
<1	39 ( 6)		1.00			1.00
1–2	60 (14)	0.17	1.95	0.75 – 5.10	0.093	2.31	0.87–6.13
>2	95 (34)	0.12	1.98	0.83 – 4.72	0.14	2.01	0.80–5.02
Type of neoadjuvant ADT
LH/RH monotherapy/orchiectomy	137 (43)
Total androgen blockade	59 (11)	0.41	0.76	0.39 – 1.47
Age	196 (54)	0.74	1.01	0.97 – 1.05
Race
Others	169 (43)		1.00			1.00
African-American	27 (11)	0.048	1.95	1.01 – 3.79	0.22	1.57	0.76–3.28
Radiation dose (Gy)	196 (54)	0.82	1.01	0.93 – 1.09

Abbreviations: pre-RT PSA = pre- radiation therapy prostate specific antigen, iPSA = pre-treatment prostate specific antigen, ADT = androgen deprivation therapy, HR = hazard ration, 95% CI = 95% confidence interval.

^*After univariate analyses, factors that reached a p-value of 0.25 or less were included in a multivariate model.